Status:
COMPLETED
Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms
Lead Sponsor:
S.LAB (SOLOWAYS)
Collaborating Sponsors:
Center of New Medical Technologies
Triangel Scientific
Conditions:
LDL Hyperlipoproteinemia
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Eligibility:
All Genders
40-75 years
Phase:
NA
Brief Summary
In this study, 102 patients will be evenly randomized into two groups: one set to receive omega-3 fatty acids and the other a placebo. The process will be blinded, ensuring that neither the researcher...
Eligibility Criteria
Inclusion
- Age between 40 and 75;
- ( LDL-C level between 70 and 190 mg/dL, confirmed in at least two sequential checks conducted within the last six months prior to signing the consent form.
Exclusion
- Personal history of cardiovascular disease or hight risk (≥ 20%);
- Triglycerides (TG) ≥ 400 mg/dL;
- Obesity (Body Mass Index \> 32 kg/m2);
- Assumption of lipid-lowering drugs or supplements affecting lipid metabolism within the last three months;
- Diabetes mellitus;
- Known severe or uncontrolled thyroid, liver, renal, or muscle diseases.
Key Trial Info
Start Date :
February 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2022
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT06154408
Start Date
February 10 2022
End Date
November 1 2022
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center of New Medical Technologies
Novosibirsk, Novosibisk Region, Russia, 630090